Login / Signup

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Roy S HerbstYi-Long WuThomas JohnChristian GroheMargarita MajemJie WangTerufumi KatoJonathan Wade GoldmanKonstantin LaktionovSang-We KimChong-Jen YuHuu Vinh VuShun LuKye Young LeeGuzel MukhametshinaCharuwan AkewanlopFilippo de MarinisLaura BonannoManuel DómineFrances A ShepherdDamien UrbanXiangning HuangAna BolanosMarta StachowiakMasahiro Tsuboi
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
These updated data demonstrate prolonged DFS benefit over placebo, reduced risk of local and distant recurrence, improved CNS DFS, and a consistent safety profile, supporting the efficacy of adjuvant osimertinib in resected EGFR-mutated NSCLC.
Keyphrases